Nasdaq · Healthcare
Metagenomi Therapeutics, Inc. (MGX)
As-reported financials and recent SEC filings for Metagenomi Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$25.2M
Net income
$-87.9M
Net margin
—
Diluted EPS
$-2.36
ROE
-55.4%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2024 |
|---|---|---|---|
| Revenue | $25.2M | $52.3M | $44.8M |
| Gross profit | — | — | — |
| Operating income | $-96.0M | $-88.9M | $-78.5M |
| Net income | $-87.9M | $-78.1M | $-68.3M |
| Diluted EPS | $-2.36 | $-2.36 | $-2.00 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →8-K2026-06-10
View on EDGAR →Largest Healthcare peers
Go deeper on MGX
Search Metagenomi Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.